BioNTech Results Presentation Deck

Poised to Accelerate Our Transformation 39 Rapidly advance pipeline 15 Oncology product candidates in 19 ongoing clinical trials 3 Phase 2 trials started in 2021 5 First-in-human trial starts in 2021 6 program updates at SITC Expansion into new class of Precision Antibacterials KA ку Expand integrated infrastructure Expansion of team to more than 2,800 professionals globally Significant investments in digital Further scale-up of Marburg mRNA manufacturing site Planning further mRNA manufacturing sites in Africa and Singapore Increase global footprint Continued expansion in U.S. with acquisition of cGMP Kite Cell Therapy manufacturing facility Planning to establish Southeast Asia headquarters in Singapore. BioNTech R&D Austria established through Phago Med acquisition ........ ........ Building long-term value for patients, investors and and society as we advance our vision of harnessing the immune system's full potential to fight human disease BIONTECH

View entire presentation